Uses for non-autologous mesenchymal stem cells

• US 20020064519A1
• Filed: 01/14/2002
• Published: 05/30/2002
• Est. Priority Date: 03/13/1998
• Status: Active Grant

• Current Assignee: Mesoblast International Srl
• Original Assignee: Daniel R. Marshak, Joseph P. Mosca, Kevin R. Mcintosh, Scott P. Bruder
• Inventors: Mosca, Joseph P., McIntosh, Kevin R., Bruder, Scott P., Marshak, Daniel R.
• Granted Patent: US 7,029,666 B2
• Time in Patent Office: Days
• US Class Current: 424/93.1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

Methods and devices using non-autologous mesenchymal stem cells comprising treating a recipient in need thereof with an effective amount of non-autologous mesenchymal stem cells, including methods and preparations for treating and regenerating connective tissue and enhancing bone marrow engraftment in an individual; and for using genetically engineered allogeneic human mesenchymal stem cells that carry within them genes of interest particularly for the expression of physiologically or pharmacologically active proteins in gene therapy for correction of genetic disorders or “rebuilding” proteins important in tissue repair.

Claims

1. A method for promoting hematopoietic or progenitor cell engraftment in an animal, comprising:

administering to an animal in need of hematopoietic or progenitor cell engraftment a therapeutically effective amount of non-autologous mesenchymal stem cells thereby promoting hematopoietic or progenitor cell engraftment.

2. The method of claim 1 wherein said animal is a human patient and said mesenchymal stem cells are allogeneic human mesenchymal stem cells.

3. The method of claim 2 wherein said allogeneic mesenchymal stem cells are obtained from an individual not MHC matched to the human patient.

4. The method of claim 1 wherein said mesenchymal stem cells are allogeneic mesenchymal stem cells.

5. The method of claim 1 wherein said animal is a human patient.

6. The method of claim 1 wherein the mesenchymal stem cells are recovered from bone marrow and are administered to the animal in a cell preparation which is substantially free of blood cells.

7. The method of claim 1 wherein the cell preparation is administered in conjunction with a carrier for the cell preparation.

8. The method of claim 7 wherein the allogeneic human mesenchymal stem cells are administered systemically.

9. The method of claim 7 wherein the preparation is administered intravenously.

10. The method of claim 1 wherein the allogeneic human mesenchymal stem cells express incorporated genetic material of interest.

11. A method for treating a human subject for promoting muscle tissue growth, comprising:

treating a recipient human subject in need of muscle tissue growth by administering a therapeutically effective amount of allogeneic mesenchymal stem cells to said recipient human subject, wherein said allogeneic mesenchymal stem cells are obtained from a donor human subject and wherein a step of MHC matching of said donor human subject is not employed prior to the administration of said allogeneic mesenchymal stem cells to the recipient human subject.

12. The method of claim 11 wherein the allogeneic human mesenchymal stem cells are recovered from human bone marrow and are administered to the recipient human subject in a cell preparation which is substantially free of blood cells.

13. The method of claim 11 wherein the cell preparation is administered in conjunction with a carrier for the cell preparation.

14. The method of claim 13 wherein the allogeneic human mesenchymal stem cells are administered systemically.

15. The method of claim 13 wherein the preparation is administered intravenously.

16. The method of claim 11 wherein the allogeneic human mesenchymal stem cells express incorporated genetic material of interest.

18. The method of claim 17 wherein said animal is a human patient.

19. The method of claim 17 wherein said mesenchymal stem cells are human mesenchymal stem cells.

17. A method of promoting connective tissue implantation in an animal comprising the steps of adhering allogeneic mesenchymal stem or progenitor cells onto the connective surface of a prosthetic device and implanting into an animal the prosthetic device containing these mesenchymal cells under conditions suitable for differentiating the cells into the type of skeletal or connective tissue needed for implantation.